# BH-501284

Source: https://onco.cc/drugs/bh-501284/  
OnCo record `bh-501284` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BH-501284 is an experimental small molecule from BlossomHill Therapeutics, in preclinical development for solid tumours.

## Summary

BH-501284 is a small molecule (oral, non-covalent) from BlossomHill Therapeutics. An orally available pan-KRAS inhibitor on a non-covalent Switch-II scaffold, designed for prolonged, selective inhibition of mutant KRAS while sparing HRAS and NRAS. Its furthest stage is preclinical development, for solid tumours (KRAS-mutant). No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline shows IND-enabling. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: BH-501284
- Modality: Small molecule (oral, non-covalent)
- Mechanism: An orally available pan-KRAS inhibitor on a non-covalent Switch-II scaffold, designed for prolonged, selective inhibition of mutant KRAS while sparing HRAS and NRAS.

## Sources

- BlossomHill Therapeutics: bhtherapeutics.com: https://www.bhtherapeutics.com/pipeline

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- companies: [BlossomHill Therapeutics](https://onco.cc/companies/blossomhill-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/bh-501284.json